



Strongly committed

At Quest Diagnostics, we take seriously our responsibility to promote a healthier world, create an inspiring and welcoming workplace, and build long-term sustainable value for all our stakeholders. In 2021, we continued our efforts to increase access to healthcare and build a high-performing and inclusive culture by investing in the development and support of our employees. We engaged our communities through corporate giving and volunteerism, took further steps to reduce our environmental footprint, and remained committed to strong and ethical governance with oversight from a diverse Board of Directors. As we move forward in 2022, we expect to continue to advance our goals.

Opening our new Clifton lab

This past year, we proudly began operations at our new flagship laboratory in Clifton, NJ. The Clifton lab is a powerful diagnostic engine for the Northeast region and the 40 million people it serves. Highly modernized, operationally efficient, and "always on," every inch of this 250,000-square-foot facility was built to serve patients and healthcare providers even better with advanced technology and world-class automation. The largest in the Quest network of more than 20 major laboratory facilities across the nation and one of the largest globally, the Clifton lab redefines what's possible in transforming the future of healthcare.

Expanding access



OJIVI COVID-19 molecular & antibody tests*

~7,100 US patient access points ~230 locations at select Walmart and Safeway locations nationwide **↓** ~50%


increase in users registered for MyQuest[®] to **21.5M**



121 new tests



Adding value



*US employees.



To read the full 2021 Corporate Responsibility Report, <u>click here</u>.

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—[®] and TM— are the property of their respective owners. [®] 2022 Quest Diagnostics Incorporated. All rights reserved. MI11319 7/2022